Molecular Partners Ag (MOLN) EBT (2020 - 2026)

Molecular Partners Ag (MOLN) has reported EBT for 7 consecutive years, with -$17.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT rose 30.36% year-over-year to -$17.2 million in Q2 2026; TTM through Jun 2026 was -$64.6 million, a 13.97% increase from a year earlier, with the FY2025 full-year figure at -$74.4 million, down 21.05% from the prior year.
• EBT was -$17.2 million for Q2 2026 at Molecular Partners Ag, down from -$16.8 million in the prior quarter.
• Over five years, EBT peaked at $165.8 million in Q1 2022 and troughed at -$24.6 million in Q2 2025.
• A 5-year average of -$6.1 million and a median of -$16.3 million in 2023 frame the typical range for EBT.
• Across the five-year window, EBT jumped 1005.57% in 2022 and slumped 278.7% in 2023, its largest moves.
• Over 5 years, EBT stood at -$18.1 million in 2022, then retreated by 23.25% to -$22.3 million in 2023, then surged by 42.51% to -$12.8 million in 2024, then declined by 23.42% to -$15.8 million in 2025, then retreated by 8.45% to -$17.2 million in 2026.
• The last three EBT figures came in at -$17.2 million (Q2 2026), -$16.8 million (Q1 2026), and -$15.8 million (Q4 2025), per Business Quant data.